Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Manca, Paolo, Russano, Marco, Pantano, Francesco, Tonini, Giuseppe, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601795/
https://www.ncbi.nlm.nih.gov/pubmed/28938699
http://dx.doi.org/10.18632/oncotarget.17607
_version_ 1783264458841260032
author Manca, Paolo
Russano, Marco
Pantano, Francesco
Tonini, Giuseppe
Santini, Daniele
author_facet Manca, Paolo
Russano, Marco
Pantano, Francesco
Tonini, Giuseppe
Santini, Daniele
author_sort Manca, Paolo
collection PubMed
description We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib.
format Online
Article
Text
id pubmed-5601795
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56017952017-09-21 Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib Manca, Paolo Russano, Marco Pantano, Francesco Tonini, Giuseppe Santini, Daniele Oncotarget Case Report We report the case of a patient affected by advanced EGFR mutation-positive lung who experienced resistance to therapy during treatment with Afatinib through the occurrence of a switch of tumor histotype to small cell lung cancer (SCLC) with features of a G3 neuroendocrine carcinoma. Unexpectedly, the switch to SCLC histotype occurred in the only site not responsive to afatinib and subsequently the most responsive to chemotherapy. Our case shows that occurrence of switch to SCLC is a possible mechanism of resistance during treatment with Afatinib. Impact Journals LLC 2017-05-04 /pmc/articles/PMC5601795/ /pubmed/28938699 http://dx.doi.org/10.18632/oncotarget.17607 Text en Copyright: © 2017 Manca et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Manca, Paolo
Russano, Marco
Pantano, Francesco
Tonini, Giuseppe
Santini, Daniele
Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title_full Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title_fullStr Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title_full_unstemmed Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title_short Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
title_sort change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601795/
https://www.ncbi.nlm.nih.gov/pubmed/28938699
http://dx.doi.org/10.18632/oncotarget.17607
work_keys_str_mv AT mancapaolo changefromlungadenocarcinomatosmallcelllungcancerasamechanismofresistancetoafatinib
AT russanomarco changefromlungadenocarcinomatosmallcelllungcancerasamechanismofresistancetoafatinib
AT pantanofrancesco changefromlungadenocarcinomatosmallcelllungcancerasamechanismofresistancetoafatinib
AT toninigiuseppe changefromlungadenocarcinomatosmallcelllungcancerasamechanismofresistancetoafatinib
AT santinidaniele changefromlungadenocarcinomatosmallcelllungcancerasamechanismofresistancetoafatinib

Ejemplares similares